SENSEX NIFTY
Sep 26, 2013, 03.55 PM IST | Source: CNBC-TV18

Sun Pharma may get windfall gains on cancer drug Doxil

The company began supplying Doxil on Special FDA importation last year owing to shortages in the US and finally received approval in Feb 2013 becoming the only other player besides the innovator in the space.

Ekta Batra

Markets Anchor & Financial Analyst, CNBC-TV18

More about the Expert...

One loss might be another one’s gain and that is applicable for Sun Pharma today. The stock is up on news that the company might reap windfall gains on one of its US drugs Doxil generic used for cancer.

Reason being, Johnson and Johnson the innovator of Doxil is facing  supply disruptions due to production issues at Ben Venue, its manufacturing partner. This means Sun Pharma will become the sole supplier in the US benefiting till J&J supplies resume (which the company said they have no current visibility on).

Also Read: Sun Pharmaceuticals files ANDAs for 4 products in Q1FY14

Analysts are optimistic on this opportunity and are of the opinion that Sun could repeat last year’s success with Doxil generic this year for example, JPM expects further gains to the US business that is estimated to grow an already robust 25% in FY14 to USD 1.4 billion (Sun sold USD 120 million worth of Doxil in CY12 and USD 63 million YTD in CY13).

On a side note, this drug seems to be lucky for Sun Pharma. The company began supplying the drug on Special FDA importation last year owing to shortages in the US and finally received approval in Feb 2013 becoming the only other player besides the innovator in the space.

Sun Pharma stock price

On December 19, 2014, Sun Pharmaceutical Industries closed at Rs 809.25, down Rs 3.5, or 0.43 percent. The 52-week high of the share was Rs 932.00 and the 52-week low was Rs 552.50.


The latest book value of the company is Rs 35.77 per share. At current value, the price-to-book value of the company was 22.62.

Set email alert for

ADS BY GOOGLE

video of the day

Rupee weakness modest, see yields at 7.60% in Q1: Deutsche

Explore Moneycontrol

Copyright © e-Eighteen.com Ltd. All rights reserved. Reproduction of news articles, photos, videos or any other content in whole or in part in any form or medium without express written permission of moneycontrol.com is prohibited.